MedTrace Logo

Evaluation of the NOVATECH ® LUCIOLA TM EB Fiducial Marker During Radiotherapy Sessions in Lung Cancer Patients

NCT05068973 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2023-01-27

No results posted yet for this study

Summary

Following CE certification, this Post Market Clinical Follow-up investigates the performance and safety of using the new fiducial marker, NOVATECH® LUCIOLA™ EB, in the lung airways to monitor in real-time tumor location during radiotherapy.

At the time of insertion near the tumor, the Luciola's 3 fiducial marker arms are deployed simultaneously. Optimal detection of the fiducial marker is considered during the radiotherapy treatment.

Conditions

Interventions

DEVICE

NOVATECH® LUCIOLA™ EB - (Fiducial Marker)

Bronchoscopic implantation in the lung of the NOVATECH® LUCIOLA™ EB fiducial marker

Sponsors & Collaborators

  • NOVATECH SA

    collaborator UNKNOWN

  • Hospital St. Joseph, Marseille, France

    lead OTHER

Principal Investigators

  • Bruno Escarguel, MD · Hôpital Saint Joseph, Marseille France

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-18
Primary Completion
2024-09-01
Completion
2025-03-01

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05068973 on ClinicalTrials.gov